Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Reexamination Certificate
2011-04-05
2011-04-05
Landsman, Robert (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
C530S351000
Reexamination Certificate
active
07919078
ABSTRACT:
The present invention provides IFNα2 mutants and active fragments, analogs, derivatives, and variants thereof, nucleotide molecules encoding same, pharmaceutical compositions containing the same, and methods utilizing the same for treating cancer, infectious diseases, and autoimmune diseases.
REFERENCES:
patent: 4588585 (1986-05-01), Mark et al.
patent: 4766106 (1988-08-01), Katre et al.
patent: 4917888 (1990-04-01), Katre et al.
patent: 5382657 (1995-01-01), Karasiewicz et al.
patent: 5609868 (1997-03-01), Lowther et al.
patent: 6214966 (2001-04-01), Harris
patent: 7141547 (2006-11-01), Rosen et al.
patent: 2004/0002474 (2004-01-01), Heinrichs et al.
patent: 2004/0132977 (2004-07-01), Gantier et al.
patent: 2004/0230040 (2004-11-01), Cox, III
patent: 2007/0148739 (2007-06-01), Jones et al.
patent: WO 93/04699 (1993-03-01), None
patent: WO 97/12630 (1997-04-01), None
patent: WO 01/54678 (2001-08-01), None
patent: WO 02/066649 (2002-08-01), None
patent: WO 2004/022747 (2004-03-01), None
patent: WO 2004/089280 (2004-10-01), None
patent: WO 2005/016371 (2005-02-01), None
patent: WO 2006/020580 (2006-02-01), None
Argos, “A possible homology between immunodeficiency virus p24 core protein and picornaviral VP2 coat protein: prediction of HIV p24 antigenic sites,” The EMBO Journal, 8(3): 779-785 (1989).
Chawla-Sarkar et al., “Preferential Induction of Apoptosis by Interferon (IFN)-β Compared with IFN-α2: Correlation with TRAIL/Apo2L Induction in Melanoma Cell Lines,” Clinical Cancer Research, 7: 1821-1831 (2001).
Gilli et al., “Neutralizing antibodies against IFN-β in multiple sclerosis: antagonization of IFN-β mediated suppression of MMPs,” Brain, 127: 259-268 (2004).
Hu et al., “Human IFN-α Protein Engineering: The Amino Acid Residues at Positions 86 and 90 are Important for Antiproliferative Activity,” The Journal of Immunology, 167: 1482-1489 (2001).
Jaitin et al., “Inquiring into the Differential Action of Interferons (IFNs): an IFN-α2 Mutant with Enhanced Affinity to IFNAR1 is Functionally Similar to IFN-β,” Molecular and Cellular Biology, 26(5): 1888-1897 (2006).
Kalie et al., “An Interferon α2 Mutant Optimized by Phage Display for IFNAR1 Binding Confers Specifically Enhanced Antitumor Activities,” The Journal of Biological Chemistry, 282(15): 11602-11611 (2007).
Lamken et al., “Ligand-induced Assembling of the Type 1 Interferon Receptor on Supported Lipid Bilayers,” J. Mol. Biol., 341: 303-318 (2004).
Piehler et al., “Biophysical Analysis of the Interaction of Human Ifnar2 Expressed inE. coliwith IFNα2,” J. Mol. Biol., 289: 57-67 (1999).
Piehler et al., “Mutational and Structural Analysis of the Binding Interface between Type 1 Interferons and their Receptor Ifnar2,” J. Mol. Biol., 294: 223-237 (1999).
Riss et al., “Use of Multiple Assay Endpoints to Investigate the Effects of Incubation Time, Dose of Toxin, and Plating Density in Cell-Based Cytotoxicity Assays,” Assay and Drug Development Technologies, 2(1): 51-62 (2004).
Tsutsumi et al., “Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity,” PNAS, 97(15): 8548-8553 (2000).
Zafranskaya et al., “Interferon-β therapy reduces CD4+and CD8+T-cell reactivity in multiple sclerosis,” Immunology, 121: 29-39 (2006).
Arduini, Robert M. et al., “Characterization of a Soluble Ternary Complex Formed Between Human Interferon-β-1a and its Receptor Chains”, Protein Science, vol. 8, pp. 1867-1877 (1999).
Brierley, Melissa M. et al., “IFN-α/β Receptor Interactions to Biologic Outcomes: Understanding the Circuitry”, Journal of Interferon and Cytokine Research, vol. 22, pp. 835-845 (2002).
Campbell, Iain L. et al., “Essential Role for Interferon-γ and Interleukin-6 in Autoimmune Insulin-dependent Diabetes in NOD/Wehi Mice”, Journal of Clin. Invest., vol. 87, pp. 739-742 (1991).
Chill, Jordan H., et al., “The Human Type I Interferon Receptor: NMR Structure Reveals the Moleculor Basis of Ligand Binding”, Structure, vol. 11, pp. 791-802 (2003).
Cutrone, Elizabeth C. et al., “Identification of Critical Residues in Bovine IFNAR-1 Responsible for Interferon Binding”, Journal of Biological Chemistry, vol. 276, pp. 17140-17148 (2001).
de Veer, Michael J. et al., “Functional Classification of Interferon-Stimulated Genes Identified Using Microarrays”, Journal of Leukocyte Biology, vol. 69, pp. 912-920 (2001).
Der, Sandy D. et al., “Identification of Genes Differentially Regulated by Interferon α, β, or γ Using Oligonucleotide Arrays”, Proc. National Academy Sci. USA, vol. 95, pp. 15623-15628 (1998).
Evinger, Marian et al., Antiproliferative and Antiviral Activities of Human Leukocyte Interferons, Archives of Biochemistry and Biophysics, vol. 210, pp. 319-329 (1981).
Fernandez-Martin, A. et al, “VIP Prevents Experimental Multiple Sclerosis by Downregulating Both Inflammatory and Autoimmune Components of the Disease”, Ann. N.Y. Academy of Science, vol. 1070, pp. 276-281 (2006).
Gavutis M. et al., “Lateral Ligand-Receptor Interactions on Membranes Probed by Simultaneous Fluorescence-Interference Detection”, Biophysical Journal, vol. 88, No. 6, pp. 4289-4302 (2005).
Goldman, Lisa A. et al., “Mapping Human Interferon-alpha (IFN-α2) Binding Determinants of the Type I Interferon Receptor Subunit IFNAR-1 with Human/Bovine IFNAR- 1 Chimeras”, Biochemistry Journal, vol. 37, pp. 13003-13010 (1998).
Hu, Renqiu et al., “Divergence of Binding, Signaling, and Biological Responses to Recombinant Human Hybrid IFN”, Journal of Immunology, vol. 163, pp. 854-860 (1999).
Klaus, Werner et al., “The Three-Dimensional High Resolution Structure of Human Interferon α -2a Determined by Heteronuclear NMR Spectroscopy in Solution”, Journal of Molecular Biology, vol. 274, pp. 661-675 (1997).
Kotenko, Sergei V. et al., “Full House: 12 Receptors for 27 Cytokines”, International Immunopharmacology, vol. 4, pp. 593-608 (2004).
Piehler, Jacob et al., “Fast Transient Cytokine-Receptor Interactions Monitored in Real Time by Reflectometric Interference Spectroscopy”, Analytical Biochemistry, vol. 289, pp. 173-186 (2001).
Piehler, Jacob et al., “New Structural and Functional Aspects of the Type I Interferon-Receptor Interaction Revealed by Comprehensive Mutational Analysis of the Binding Interface”, Journal of Biological Chemistry, vol. 275, No. 51, pp. 40425-40433 (2000).
Platanias, Leonidas C. et al., “Signaling Pathways Activated by Interferons”, Experimental Hematology, vol. 27, pp. 1583-1592 (1999).
Roisman, Laila C. et al., “Mutational Analysis of the IFNAR1 Binding Site on IFNα2 Reveals the Architecture of a Weak Ligand-Receptor Binding-Site”, Journal of Molecular Biology, vol. 353, pp. 271-281 (2005).
Runkel, Laura et al., “Systematic Mutational Mapping of Sites on Human Interferon-B-1a that are Important for Receptor Binding and Functional Activity”, Biochemistry, vol. 39, pp. 2538-2551 (2000).
Schmeisser, Hana et al., “Amino Acid Substitutions in Loop BC and Helix C Affect Antigenic Properties of Helix D in Hybrid IFN-α21a/α2c Molecules”, Journal of Interferon and Cytokine Research, vol. 22, pp. 463-472 (2002).
Schmitt, Hans-Martin, et al., “An Integrated System for Optical Biomolecular Interaction Analysis”, Biosensors & Bioelectronics, vol. 12, No. 8, pp. 809-816 (1997).
Uzé, Gilles et al., Genetic Transfer of a Functional Human Interferon Alpha Receptor into Mouse Cells: Cloning and Expression of its cDNA. Cell., vol. 60, pp. 225-234 (1990).
Villa Erica et al.,
Jaitin Diego
Kalie Eyal
Roisman Laila C.
Schreiber Gideon E
Hissong Bruce D
Landsman Robert
Winston & Strawn LLP
Yeda Research and Development Co. Ltd. at the Weizmann Institute
LandOfFree
Recombinant interferon α2 (IFNα2) mutants and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant interferon α2 (IFNα2) mutants and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant interferon α2 (IFNα2) mutants and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2711004